Prodegre

ProDegre Bio is an early-stage biotechnology company dedicated to advancing the field of targeted protein degradation (TPD). The company utilizes a proprietary platform to develop "Pro-Degraders," a novel class of bifunctional small molecules designed to recruit E3 ligases for the selective degradation of pathogenic proteins. By targeting proteins that are currently inaccessible to traditional small molecule inhibitors, ProDegre Bio aims to address significant unmet medical needs in oncology and other therapeutic areas. Founded by leading experts in protein homeostasis, the company is focused on optimizing the potency, selectivity, and pharmacological properties of its degrader candidates as they progress through pre-clinical development. The company's approach seeks to overcome the limitations of first-generation degraders by improving tissue specificity and reducing off-target effects.